April 22 (Reuters) - Abeona Therapeutics said on Monday the U.S. health regulator had declined to approve its treatment for a rare skin blistering condition. (Reporting by Pratik Jain in Bengaluru; Editing by Sriraj Kalluvila)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.2 USD | -5.62% | -8.70% | -16.17% |
May. 03 | Abeona Therapeutics Prices $75 Million Securities Offering; Shares Rise | MT |
Apr. 23 | Sector Update: Health Care Stocks Rise Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.17% | 115M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- ABEO Stock
- News Abeona Therapeutics Inc.
- US FDA declines to approve Abeona's skin disorder treatment